Compare Nokia Corp (NOK) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nokia Corp vs Vertex Pharmaceuticals Incorporated — how do they compare? Nokia Corp trades at $10.29 (market cap $53.00B), while Vertex Pharmaceuticals Incorporated trades at $529.98 (market cap $134.25B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 2.5× Nokia Corp's market cap, and Nokia Corp pays a 1.73% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| NOK | VRTX | |
|---|---|---|
Market Cap | $53.00B | $134.25B |
Sector | Technology | Health |
52-Week High | $16.83 | $529.65 |
52-Week Low | $4.13 | $376.62 |
Enterprise Value | $50.95B | $128.37B |
Dividend Yield | 1.73% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nokia (NOK) trades at $9.12, down 2.67% today amid a bearish technical signal, with mixed earnings performance including a Q2 2026 EPS beat. Revenue has stabilized near $20B annually, but net margins are thin at 3.47%. The company is pivoting toward AI and cloud infrastructure, with recent news highlighting demand growth in these areas. Cash flow turned negative in 2025, though the balance sheet remains solid with $8.91B in cash.
Outlook is cautiously optimistic due to AI-driven demand and insider buying, but risks include telecom spending volatility and high P/E valuation. Analyst consensus is bullish with 60% buy ratings. The stock faces near-term pressure from technical indicators but offers long-term potential if AI initiatives accelerate growth.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Nokia Corp
Nokia is a leading vendor in the telecommunications equipment industry. The company's network business derives revenue from selling wireless and fixed-line hardware, software, and services. Nokia's technology segment licenses its patent portfolio to handset manufacturers and makes royalties from Nokia-branded cellphones. The company, headquartered in Espoo, Finland, operates on a global scale, with most of its revenue from communication service providers.
Read more on NOK →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
